FDMT Insider John Milligan Buys 75,000 Shares
John Milligan's recent purchase adds to a wave of insider buying at 4D Molecular Therapeutics.
Reviewed by automated data checks against the source filing. How we make and check alerts
John Milligan bought 75,000 shares of 4D Molecular Therapeutics, Inc. ($FDMT) on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $FDMT is up 23.4% after 1 week, up 16.7% after 1 month and up 28.9% to date (from the $9.42 close on Jun 17, 2026).
FDMT
4D Molecular Therapeutics, Inc.
Key Points
- On June 17, 2026, John Milligan bought 75,000 shares of 4D Molecular Therapeutics, valued at about $724,500 based on the recent share price of $9.66.
- The stock has seen significant insider buying, with other executives like Shawn Tomasello and Nancy Miller-Rich each acquiring 50,000 shares on the same day.
- Analysts maintain a strong buy consensus on 4D Molecular Therapeutics, with a mean price target of $27.82, suggesting potential upside from current levels.
Get $FDMT trade alerts by text
We text you when insiders, Congress or big funds trade $FDMT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated 4D Molecular Therapeutics, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at 4D Molecular Therapeutics, Inc.
On June 17, 2026, John Milligan, an insider at 4D Molecular Therapeutics, Inc. (NasdaqGS: FDMT), bought 75,000 shares of the company. This purchase is valued at approximately $724,500 based on the share price of $9.66 at the time. Milligan's move comes amid a notable wave of insider buying, reflecting a strong interest from the company's leadership.
What This Purchase Means
Milligan's acquisition adds to the recent trend of insider buying at 4D Molecular Therapeutics. With this latest purchase, he joins several other executives who also bought shares on the same day. Notably, Shawn Tomasello, Nancy Miller-Rich, Jacob Chacko, Susannah Gray, Glenn Sblendorio, and Charles Theuer all acquired 50,000 shares each. This level of insider activity suggests a strong belief among the company's leaders in its future prospects.
Analysts Set New Price Targets
4D Molecular Therapeutics has garnered attention from analysts, with firms maintaining a strong buy consensus. On October 6, 2026, Chardan Capital maintained a buy rating with a price target of $25.00. Earlier, on September 29, 2026, B of A Securities also kept a buy rating, raising its target to $33.00. The consensus among analysts is a strong buy, with an average price target of around $27.82, indicating potential for growth from current levels.
Stock Performance Context
The shares of 4D Molecular Therapeutics are currently trading below their 52-week high of $16.93. The stock's recent price of $9.66 is significantly lower than this peak, suggesting that it may be undervalued given the recent insider purchases and analyst ratings. The company's market cap stands at about $841.9 million, reflecting its position in the biotechnology sector.
What 4D Molecular Therapeutics, Inc. Does
4D Molecular Therapeutics focuses on developing innovative therapies using adeno-associated virus vectors. Its lead product candidate is aimed at treating retinal vascular diseases, with additional projects in the pipeline for conditions like cystic fibrosis and geographic atrophy. The company's ongoing research and development efforts are critical to its future success.
What's Ahead for 4D Molecular Therapeutics, Inc.
Investors will be watching for the next earnings report scheduled for November 10, 2026. As this insider buying shows strong internal confidence, it will be interesting to see how these developments impact the company's performance. Remember, the recent insider transactions reflect past trades and may not represent current positions.
Related Filing Alerts
Source: John Milligan's Form 4 filing on $FDMT (Jun 17, 2026). Find the original filing: FDMT Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts